PEPTIDE YY AND PEPTIDE YY AGONISTS FOR TREATMENT OF METABOLIC DISORDERS
Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist.
1 . A method of treating obesity comprising administering to an obese subject a therapeutically effective amount of a PYY or a PYY agonist.
2 . The method of claim 1 wherein the subject is at least one of insulin resistant or glucose intolerant.
3 . The method of claim 1 wherein the subject has diabetes mellitus.
4 . The method of claim 1 wherein the PYY agonist is PYY[3-36].
5 . The method of claim 1 wherein the PYY or PYY agonist is administered peripherally.
6 . The method of claim 1 wherein about 1 μg to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.
7 . The method of claim 1 wherein about 0.01 μg/kg to about 500 μg/kg of the PYY or PYY agonist is administered per dose.
8 . A method of reducing food intake comprising administering to a subject a therapeutically effective amount of a PYY or a PYY agonist.
9 . The method of claim 8 wherein the PYY agonist is PYY[3-36].
10 . The method of claim 8 wherein the PYY or PYY agonist is administered peripherally.
11 . The method of claim 8 wherein about 1 μg to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.
12 . The method of claim 8 wherein about 0.01 μg/kg to about 500 μg/kg of the PYY or PYY agonist is administered per dose.
13 . A method of treating diabetes mellitus in a subject comprising administering an effective amount of a PYY or a PYY agonist.
14 . The method of claim 13 wherein the PYY or PYY agonist is administered peripherally.
15 . The method of claim 13 wherein the subject has Type II diabetes.
16 . The method of claim 13 wherein the subject is overweight.
17 . The method of claim 13 wherein the PYY agonist is PYY[3-36].
18 . The method of claim 13 wherein about 1 μg to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.
19 . The method of claim 13 wherein about 0.01 μg/kg to about 500 μg/kg of the PYY or PYY agonist is administered per dose.
20 . A method of improving lipid profile in a subject comprising administering to the subject an effective amount of a PYY or a PYY agonist.
21 . The method of claim 20 wherein the improvement in lipid profile comprises at least one of reducing LDL cholesterol levels, reducing triglyceride levels and increasing HDL cholesterol levels.
22 . The method of claim 20 wherein the PYY or PYY agonist is administered peripherally.
23 . A method for treating conditions or disorders which can be alleviated by reducing nutrient availability in a subject comprising administering to said subject a therapeutically effective amount of a PYY or a PYY agonist.
24 . The method of claim 23 wherein the condition or disorder is hypertension.
25 . The method of claim 23 wherein the condition or disorder is dyslipidemia.
26 . The method of claim 23 wherein the condition is cardiovascular risk.
27 . The method of claim 23 wherein the disorder is an eating disorder.
28 . The method of claim 23 wherein the condition or disorder is insulin-resistance.
29 . The method of claim 23 wherein the condition is obesity.
30 . The method of claim 23 wherein the condition is diabetes mellitus.
31 . The method of claim 23 wherein about 1 μg to about 5 mg of the PYY or PYY agonist is administered per day in single or divided doses.
32 . The method of claim 23 wherein about 0.01 μg/kg to about 500 μg/kg of the PYY or PYY agonist is administered per dose.
33 . The method of any of claims 1 , 8 , 13 , 20 , and 23 wherein the PYY agonist has a potency in at least one of a food intake or gastric emptying assay greater than NPY.